Bone-targeted therapy

J. Salmen, M. Banys-Paluchowski, T. Fehm*

*Corresponding author for this work
    6 Citations (Scopus)


    Bisphosphonates and denosumab are well established components of the therapy for osteoporosis and osseous metastases. Their relevance in the adjuvant situation for breast cancer patients is being discussed in part controversially due to the heterogeneous nature of the available data. In particular, it appears that post-menopausal women benefit from an adjuvant therapy with bisphosphonates. In the present contribution we discuss the clinical relevance of osteoprotective therapy in the metastatic and adjuvant settings. Above all the current AGO guidelines on osteo-oncology and bone health have been taken into consideration for recommendations to implement the available data.

    Original languageEnglish
    JournalGeburtshilfe und Frauenheilkunde
    Issue number6
    Pages (from-to)584-587
    Number of pages4
    Publication statusPublished - 10.06.2015


    Dive into the research topics of 'Bone-targeted therapy'. Together they form a unique fingerprint.

    Cite this